Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom Broadcom ... citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

In addition, recent price cuts for Januvia under Medicare and a one-time acquisition-related charge impacting operating margins have further pressured Merck's stock performance. Moreover ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

Merck’s MRK stock has declined 14.4% in ... Let’s understand these factors in detail to better analyze how to play the stock after the price decline. Keytruda, approved for several types ...